ASCITES HEPATIC
Clinical trials for ASCITES HEPATIC explained in plain language.
Never miss a new study
Get alerted when new ASCITES HEPATIC trials appear
Sign up with your email to follow new studies for ASCITES HEPATIC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New shunt procedure could extend life for liver patients with severe fluid retention
Disease control Recruiting nowThis study compares early placement of a small tube (TIPS) that reroutes blood flow in the liver against standard treatments like water pills and fluid drainage. The goal is to see if the shunt helps people with liver cirrhosis and severe fluid buildup live longer without needing…
Matched conditions: ASCITES HEPATIC
Phase: NA • Sponsor: University Hospital Freiburg • Aim: Disease control
Last updated Jun 15, 2026 14:40 UTC
-
Smaller stent, bigger hope: new TIPS technique aims to prevent brain fog
Disease control Recruiting nowThis study tests a technique called 'underdilated stent' during a liver shunt procedure (TIPS) for people with cirrhosis. The goal is to see if using a smaller balloon to place the stent can lower the risk of hepatic encephalopathy (brain confusion) after the procedure, while sti…
Matched conditions: ASCITES HEPATIC
Phase: NA • Sponsor: The Second Affiliated Hospital of Chongqing Medical University • Aim: Disease control
Last updated Jun 15, 2026 14:38 UTC
-
New stent graft aims to ease Life-Threatening liver complications
Disease control Recruiting nowThis study is testing a device called the LIVERTY TIPS stent graft in 166 people with cirrhosis who have complications like internal bleeding or fluid buildup. The stent is placed in the liver to create a new channel for blood flow, reducing dangerous pressure. Researchers will c…
Matched conditions: ASCITES HEPATIC
Phase: NA • Sponsor: C. R. Bard • Aim: Disease control
Last updated Jun 10, 2026 13:28 UTC
-
New drug PHIN-214 tested for liver scarring
Disease control Recruiting nowThis early-stage study is testing a new medicine called PHIN-214 in 74 adults with mild-to-moderate liver cirrhosis (Child-Pugh A or B). The main goal is to check the drug's safety and find the best dose, given either once or daily for 28 days. This is a Phase 1 trial, so it focu…
Matched conditions: ASCITES HEPATIC
Phase: PHASE1 • Sponsor: PharmaIN • Aim: Disease control
Last updated Jun 03, 2026 12:03 UTC